Hyperion DeFi (NASDAQ:HYPD) Cut to “Strong Sell” at Zacks Research

Hyperion DeFi (NASDAQ:HYPD) was downgraded by equities researchers at Zacks Research from a “hold” rating to a “strong sell” rating in a research note issued on Wednesday,Zacks.com reports.

A number of other equities research analysts also recently commented on HYPD. Cantor Fitzgerald lifted their target price on Hyperion DeFi from $6.60 to $7.10 and gave the company an “overweight” rating in a research report on Thursday. Chardan Capital reiterated a “buy” rating and set a $7.30 price target on shares of Hyperion DeFi in a report on Tuesday. Finally, Weiss Ratings raised Hyperion DeFi from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, June 24th. Two research analysts have rated the stock with a Buy rating and two have given a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $7.20.

Hyperion DeFi Stock Up 5.2%

HYPD stock opened at $2.83 on Wednesday. The firm has a market cap of $42.90 million, a PE ratio of -0.43 and a beta of 2.53. The company has a debt-to-equity ratio of 0.12, a quick ratio of 1.97 and a current ratio of 1.97. The firm’s 50 day moving average price is $2.91 and its 200-day moving average price is $3.36. Hyperion DeFi has a one year low of $2.34 and a one year high of $15.00.

Hyperion DeFi (NASDAQ:HYPD) last released its quarterly earnings data on Thursday, August 13th. The company reported $0.92 EPS for the quarter. The firm had revenue of $0.36 million for the quarter. Hyperion DeFi had a negative return on equity of 13.93% and a net margin of 416.56%. On average, equities research analysts anticipate that Hyperion DeFi will post 1.69 EPS for the current year.

Insider Buying and Selling

In other news, insider Hyunsu Jung purchased 7,000 shares of the stock in a transaction dated Monday, June 1st. The stock was acquired at an average cost of $3.70 per share, for a total transaction of $25,900.00. Following the completion of the transaction, the insider directly owned 1,384,676 shares in the company, valued at approximately $5,123,301.20. This represents a 0.51% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at this link. 7.50% of the stock is owned by company insiders.

Hedge Funds Weigh In On Hyperion DeFi

Several hedge funds have recently bought and sold shares of the company. Renaissance Technologies LLC purchased a new position in Hyperion DeFi during the 4th quarter valued at about $663,000. Jane Street Group LLC purchased a new stake in Hyperion DeFi during the fourth quarter worth about $493,000. Focus Partners Advisor Solutions LLC purchased a new stake in Hyperion DeFi during the fourth quarter worth about $221,000. Geode Capital Management LLC acquired a new stake in shares of Hyperion DeFi during the fourth quarter worth about $214,000. Finally, Investment House LLC acquired a new stake in shares of Hyperion DeFi during the fourth quarter worth about $166,000. Institutional investors and hedge funds own 25.84% of the company’s stock.

About Hyperion DeFi

Eyenovia, Inc, an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis.